Cart
sales@molnova.com
EGFR-IN-9
CAS No. 1226549-39-8
EGFR-IN-9( —— )
Catalog No. M32908 CAS No. 1226549-39-8
EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 73 | Get Quote |
|
| 5MG | 107 | Get Quote |
|
| 10MG | 170 | Get Quote |
|
| 25MG | 319 | Get Quote |
|
| 50MG | 487 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEGFR-IN-9
-
NoteResearch use only, not for human use.
-
Brief DescriptionEGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.
-
DescriptionEGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.
-
In VitroEGFR-IN-9 (Compound 8) shows antiproliferative activity in HCC827 lung cancer cell line with an IC50 of 8 nM.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1226549-39-8
-
Formula Weight476.53
-
Molecular FormulaC29H24N4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (209.85 mM; Ultrasonic )
-
SMILESOC[C@@H](Nc1ncnc2oc(c(-c3cccc(NC(=O)C=C)c3)c12)-c1ccccc1)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Coumar MS, et al. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor leadidentification. J Med Chem. 2010 Jul 8;53(13):4980-8.?
molnova catalog
related products
-
Afatinib
An irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
-
XL-647
XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.
-
LDC4297
LDC4297 is a potent and selective CDK7 inhibitor.
